子類別 圖書 [5/7] 會議論文/會議摘要 [25/32] 期刊論文 [158/158] 鄰近社群 MARK LAWRENCE WAHLQVIST(2008-2012) [138/140] 吳易謙 [54/55] 吳秀英 [10/10] 廖本揚 [39/39] 廖玉潔 [63/65] 張新儀 [245/268] 李孟智 [51/54] 李蘭 [28/28] 林培生 [25/25] 林煜軒 [47/47] 林肇堂 [35/35] 梁賡義 [15/15] 江博煌 [72/78] 溫啟邦(2001-2010) [177/188] 潘文涵 [110/115] 熊昭 [369/379] 莊淑鈞 [43/44] 莊紹源 [162/168] 蔡慧如 [162/165] 蔡憶文(1999-2010) [34/34] 藍祚運(2003-2011) [22/23] 許志成 [385/393] 邱亞文(2005-2013) [63/99] 邱弘毅 [49/49] 邱燕楓 [82/82] 郭耿南(2003-2010) [89/105] 鄒小蕙 [101/105] 鍾仁華 [85/86] 陳主智 [61/61] 陳慶餘(2006-2010) [70/70] 陳美惠 [32/32] 陳豐奇 [53/55] 陳麗光 [106/106] 黃國晉 [15/15] 丘政民(2000-2004) [8/8] 其他 [238/244] 劉仁沛(1998-2002) [64/65] 姚姿君(1999-2002) [3/3] 戴東原(2003-2005) [21/22] 李明亮(2003-2007) [6/6] 林仲彥(1999-2005) [31/33] 林錦瑜(2002-2003) [5/5] 涂醒哲(2003-2004) [4/4] 石曜堂(1999-2006) [20/24] 蔡碧紋(2004-2006) [3/4] 陳淑媛(2001-2004) [3/3] 社群統計 近3年內發表的文件:19(9.64%) 含全文筆數:188(95.43%) 文件下載次數統計 下載大於0次:188(100.00%) 下載大於100次:177(94.15%) 檔案下載總次數:95439(1.78%) 最後更新時間: 2024-12-01 15:25 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Registry of genetic alterations of ... A statistical method for protocol m... Immune killer cells treatment for p... Survival of advanced/recurrent gast... The clinical characteristics and ma... A phase 1 study of biweekly nab-pac... The registry of genetic alterations... Nivolumab plus ipilimumab (N plus I... Polygenic risk score, environmental... Genome-wide association study of lu...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目1-50 / 197. (共4頁) 1 2 3 4 > >> 每頁顯示[10|25|50]項目

日期	題名	關聯
2024-10	A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study	Oncologist. 2024 Oct 3;29(10):e1396-e1405.
2024-09-30	Registry of genetic alterations of Taiwan non-small cell lung cancer by comprehensive next-generation sequencing: A real-world cohort study-Taiwan cooperative oncology group T1521	JCO Global Oncology. 2024 Sep 30;10:Article number e2400125.
2024-08-28	A statistical method for protocol modifications with heterogeneous population variances	Statistics in Biopharmaceutical Research. 2024 Aug 28;Article in Press.
2024-08-21	Immune killer cells treatment for previously treated stage IV NSCLC patients	Scientific Reports. 2024 Aug 21;14:Article number 19374.
2024-07-11	Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: A nationwide registry study	BMC Cancer. 2024 Jul 11;24:Article number 828.
2024-06-24	The clinical characteristics and manifestation of anxious depression among patients with major depressive disorders-results from a Taiwan multicenter study	Psychiatry Investigation. 2024 Jun 24;21(6):561-572.
2023-11-13	Polygenic risk score, environmental tobacco smoke, and risk of lung adenocarcinoma in never-smoking women in Taiwan	JAMA Network Open. 2023 Nov 13;6(11):Article number e2339254.
2023-11	Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome	Annals of Oncology. 2023 Nov;34(Suppl. 3):S1390.
2023-11	The registry of genetic alterations of Taiwan NSCLC by comprehensive next-generation sequencing: A real-world cohort study - TCOG T1521 study	Journal of Thoracic Oncology. 2023 Nov;18(11, Suppl.):S52.
2023-05-26	Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population	Nature Communications. 2023 May 26;14:Article number 3043.
2023-05	Bayesian hierarchical models for adaptive basket trial designs	Pharmaceutical Statistics. 2023 May-Jun;22(3):531-546.
2022-12	Recalibrating risk prediction models by synthesizing data sources: Adapting the lung cancer PLCO model for Taiwan	Cancer Epidemiology, Biomarkers and Prevention. 2022 Dec 5;31(12):2208-2218.
2022-11	BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma	Annals of Oncology. 2022 Nov;33(Suppl. 9):S1472-S1473.
2022-10	Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract Cancer: A phase II T1219 study	Clinical Cancer Research. 2022 Oct 3;28(19):4248-4257.
2022-07	A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer	Annals of Oncology. 2022 Jul;33(Suppl. 6):S478.
2022-06-02	Trial Designs for integrating novel therapeutics into the management of intermediate-stage hepatocellular carcinoma	Journal of Hepatocellular Carcinoma. 2022 Jun 2;9:517-536.
2022-06	Three-stage pooled plasma hepatitis C virus RNA testing for the identification of acute HCV infections in at-risk populations	Microbiology Spectrum. 2022 Jun 29;10(3):Article number e0243721.
2022-01	Use of likelihood estimates for variances for the design and evaluation of multiregional clinical trials with heterogeneous variances	Statistics in Medicine. 2022 Jan 15;41(1):87-107.
2022-01	Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients	Clinical and Translational Radiation Oncology. 2022 Jan;32:59-68.
2021-11-12	The prognostic and predictive role of chromogranin a in gastroenteropancreatic neuroendocrine tumors - A single-center experience	Frontiers in Oncology. 2021 Nov 12;11:Article number 741096.
2021-09-27	Comment on"Biostatistical considerations when using RWD and RWE in clinical studies for regulatory purposes: A landscape assessment": Is real-world evidence real?	Statistics in Biopharmaceutical Research. 2021 Sep 27;15(1):18-19.
2021-09	A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer	Annals of Oncology. 2021 Sep;32(Suppl. 5):S377.
2021-05	High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial	Radiotherapy and Oncology. 2021 May;158:146-154.
2021-05	TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma	Journal of Clinical Oncology. 2021 May;39(15, Suppl.):4143.
2021-05	A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy	Journal of Clinical Oncology. 2021 May;39(15, Suppl.):Abstract number 6025.
2021-02-05	Tolerance interval testing for assessing accuracy and precision simultaneously	PLoS ONE. 2021 Feb 5;16(2):Article number e0246642.
2021-02	On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes	Contemporary Clinical Trials. 20201 Feb;101:Article number 106244.
2021-01	Use of a two-sided tolerance interval in the design and evaluation of biosimilarity in clinical studies	Pharmaceutical Statistics. 2021 Jan;20(1):175-184.
2020-12-29	Sub-multiplicative interaction between polygenic risk score and household coal use in relation to lung adenocarcinoma among never-smoking women in Asia	Environment International. 2020 Dec 29;147:Article number 105975.
2020-12-02	A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)	PLoS ONE. 2020 Dec 2;15(12):Article number e0242763.
2020-11	Use of tolerance intervals for assessing biosimilarity	Statistics in Medicine. 2020 Nov;39(26):3806-3822.
2020-10	Operational experiences in China and statistical issues on the conduct of clinical trials during the COVID-19 pandemic	Statistics in Biopharmaceutical Research. 2020 Oct;12(4):438-442.
2020-09-02	Use of a tolerance interval approach as a statistical quality control tool for traditional Chinese medicine	Journal of Biopharmaceutical Statistics. 2020 Spe 2;30(5):873-881.
2020-07-01	A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue	Haematologica. 2020 Jul 1;105(7):e349-e354.
2020-05	An open-label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy of TLC388 and genomic analysis for poorly differentiated neuroendocrine carcinomas	Oncologist. 2020 May;25(5):e782-e788.
2020-04-21	Impact of cooking oil fume exposure and fume extractor use on lung cancer risk in non-smoking Han Chinese women	Scientific Reports. 2020 Apr 21;10:Article number 6774.
2020-03	Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women	Genomics. 2020 Mar;112(2):1223-1232.
2020-02	Predicting lung cancer occurrence in never-smoking females in Asia: TNSF-SQ, a prediction model	Cancer Epidemiology, Biomarkers and Prevention. 2020 Feb;29(2):452-459.
2020-01	Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection	Journal of the Formosan Medical Association = Taiwan Yi Zhi. 2020 Jan;119(1):335-344.
2020-01	A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma–TCOG T1211 study	European Journal of Cancer. 2020 Jan;124:123-130.
2019-07	Use of interval estimations in design and evaluation of multiregional clinical trials with continuous outcomes	Statistical Methods in Medical Research. 2019 Jul;28(7):2179-2195.
2019-05	An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14)	Journal of Clinical Oncology. 2019 May;37(15, Suppl. S):Abstract number 4101.
2018-09	Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study	Annals of Oncology. 2018 Sep;29(9):1972-1979.
2018-08-21	Design and data analysis of multiregional clinical trials (MRCTs)—Theory and practice	Biopharmaceutical Applied Statistics Symposium : Design of Clinical Trials. 2018 Aug 21;Chapter 10:269-286.
2018-07	The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients	Journal of the Chinese Medical Association. 2018 Jul;81(7):593-598.
2018-01	Use of a Bayesian approach in the design and evaluation of NCE2s	Journal of Food and Drug Analysis. 2018 Jan;26(1):416-421.
2017-11-23	Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy	Scientific Reports. 2017 Nov 23;7:Article number 16187.
2017-11	Intake of potassium- and magnesium-enriched salt improves functional outcome after stroke: A randomized, multicenter, double-blind controlled trial	American Journal of Clinical Nutrition. 2017 Nov;106(5):1267-1273.
2017-10	Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma	Asia Pacific Journal of Clinical Nutrition. 2017 Oct;13(5):E304-E311.
2017-09	A tolerance interval approach to assessing the biosimilarity of follow-on biologics	Statistics in Biopharmaceutical Research. 2017 Sep;9(3):286-292.

顯示項目1-50 / 197. (共4頁) 1 2 3 4 > >> 每頁顯示[10|25|50]項目